|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Global Immunology Industry Report mentions that generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents. However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.
View Complete Report @ http://www.reportsweb.com/global-immunology-market-to-2022-large-pipeline-and-competitive-market-to-drive-long-term-market-growth
Other Key Points in Report:
Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
-What factors are driving the market growth?
-How can the factors limiting growth be overcome?
There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.
-What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
-How does the composition of the pipeline compare with that of the existing market?
Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.
-How will this affect their revenues in this period?
-How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170038/buying
Table of Content: An Overview
2 Introduction 8
2.1 Therapy Area Introduction 8
2.2 Symptoms 8
2.3 Etiology and Pathophysiology 9
2.4 Co-morbidities and Complications 11
2.5 Epidemiology Patterns and Forecasts-Prevalence, Patient Segmentation, Diagnostic and Treatment Usage Rates
2.5.1 Rheumatoid Arthritis 12
2.5.2 Psoriasis 13
2.5.3 Systemic Lupus Erythematosus 14
2.6 Treatment 15
2.6.1 Non-Biologic Disease-Modifying Anti-Rheumatic Drugs 16
2.6.2 Glucocorticoids 17
2.6.3 Biologics 17
3 Key Marketed Products 19
3.1 Overview 19
3.2 Humira (adalimumab) 21
3.3 Remicade (infliximab) 22
3.4 Enbrel (etanercept) 24
3.5 Rituxan (rituximab) 26
3.6 Stelara (ustekinumab) 27
3.7 Prograf (tacrolimus) 28
3.8 Cimzia (certolizumab pegol) 30
3.9 Simponi (golimumab) 31
3.10 Conclusion 33
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170038/discount
4 Pipeline Landscape Assessment 34
4.1 Overview 34
4.2 Pipeline Development Landscape 34
4.3 Molecular Targets in the Pipeline 37
4.4 Clinical Trials 39
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 40
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 43
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 47
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 51
4.5 Conclusion 56
5 Multi-Scenario Market Forecast to 2022 57
5.1 Overall Market Size 57
5.2 Generic Penetration 60
5.3 Revenue Forecast by Molecular Target 61
5.3.1 Tumor Necrosis Factor-Alpha 62
5.3.2 Interleukin-6 and Interleukin-6 Receptor 63
5.3.3 Interleukins-1, 2, 5, 12, 17 and 23 and Receptors 63
5.3.4 Janus Kinases 64
5.3.5 Revenue and Market Share Analysis by Company 65
5.3.6 Assessment of Key Pipeline Products 74
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170038/buy/4995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
